Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab (MEDI4736) Monotherapy in Recurrent/Metastatic SCCHN (HAWK)
NCT02207530Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Sep 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 14
01
Overview
A Phase 2 trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by AstraZeneca. Started Oct 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02207530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207530.